SCHEMBL472172

SCHEMBL472172

Clc1nc2cc3ccccc3cc2nc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.65
NQO2 P16083 3/20 0.62
KMT2A Q03164 3/20 0.48
MAPT P10636 3/20 0.47
CYP2A6 P11509 1/20 0.46
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
GLA P06280 1/20 0.43
ACHE P22303 1/20 0.43
RPS6KB2 Q9UBS0 1/20 0.43
KDM4E B2RXH2 2/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PI4KA P42356 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30969485 1.00 TDP1 (0.65) TDP1NQO2KMT2AMAPTCYP2A6
SCHEMBL7698365 0.84 NQO2 (0.50) TDP1NQO2KMT2AMAPTCYP2A6
SCHEMBL13156487 0.82 NQO2 (0.88) TDP1NQO2KMT2AMAPTCYP2A6
SCHEMBL23024890 0.80 KDM4E (0.74) TDP1NQO2KMT2AMAPTALDH1A1
SCHEMBL29451077 0.79 TDP1 (1.00) TDP1NQO2KMT2AMAPTALDH1A1
SCHEMBL116696 0.79 TDP1 (1.00) TDP1NQO2KMT2AMAPTALDH1A1
SCHEMBL11540011 0.78 TDP1 (0.56) TDP1NQO2KMT2AMAPTALDH1A1
SCHEMBL29237003 0.77 MAPT (0.56) TDP1NQO2KMT2AMAPTCYP2A6
Benzo[B]Phenazine SCHEMBL5481172 0.77 NQO2 (1.00) TDP1NQO2KMT2AMAPTALDH1A1
SCHEMBL2247546 0.77 NQO2 (0.68) TDP1NQO2KMT2AMAPTCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002094796-A2 BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES AXXIMA PHARMACEUTICALS AG (DE) 2002-11-28 WO claimed
CN-117942786-A Preparation method of nanofiltration membrane and nanofiltration membrane prepared by same 沃顿科技股份有限公司 2024-04-30 CN disclosed
EP-3325486-B1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES UNIV ORLEANS (FR) 2023-05-24 EP disclosed
EP-3325486-B1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES UNIV ORLEANS (FR) 2023-05-24 EP disclosed
US-10954436-B2 Polynitrogen compounds and uses thereof as fluorescent chromophores UNIVERSITE D'ORLEANS (FR) 2021-03-23 US disclosed
US-10954436-B2 Polynitrogen compounds and uses thereof as fluorescent chromophores UNIVERSITE D'ORLEANS (FR) 2021-03-23 US disclosed
US-20180194997-A1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-07-12 US disclosed
US-20180194997-A1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-07-12 US disclosed
EP-3325486-A1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES Universite D'Orleans (FR) 2018-05-30 EP disclosed
WO-2017013135-A1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES UNIVERSITE D'ORLEANS (FR) 2017-01-26 WO disclosed
EP-1325009-B1 AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL MYERS SQUIBB CO (US) 2006-03-08 EP disclosed
US-6960585-B2 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-01 US disclosed
US-6869956-B2 Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) BRISTOL-MYERS SQUIBB COMPANY (US) 2005-03-22 US disclosed
EP-1363993-A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) Bristol-Myers Squibb Company (US) 2003-11-26 EP disclosed
EP-1325009-A2 AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Bristol-Myers Squibb Company (US) 2003-07-09 EP disclosed
US-20030022898-A1 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) BRISTOL-MYERS SQUIBB COMPANY 2003-01-30 US disclosed
WO-2002094796-A2 BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES AXXIMA PHARMACEUTICALS AG (DE) 2002-11-28 WO disclosed
WO-2002060386-A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-08 WO disclosed
US-20020072523-A1 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2002-06-13 US disclosed
WO-2002028860-A2 AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194997-A1 POLYNITROGEN COMPOUNDS AND USES THEREOF AS FLUORESCENT CHROMOPHORES PNN, NCL, NUCB2 TDP1 799/4885NQO2 246/4885KMT2A 4430/4885
US-20020072523-A1 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same IL4, IL4I1, MSR1 TDP1 1986/4885NQO2 1631/4885KMT2A 2115/4885
US-10954436-B2 Polynitrogen compounds and uses thereof as fluorescent chromophores PNN, NCL, NUCB2 TDP1 799/4885NQO2 246/4885KMT2A 4430/4885
US-20030022898-A1 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) NFKBIA, IKBKG, IKBKB TDP1 1259/4885NQO2 103/4885KMT2A 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.